{"product_id":"tiragolumabrg6058-mtig7192a-10mg","title":"Tiragolumab(RG6058\/MTIG7192A) 10mg","description":"\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eDue to the nature of this product being a monoclonal antibody and thus must be manufactured and stored under stringent quality standards, order fulfillment requires additional processing time. Please allow 2–3 weeks for production, plus shipping time, to ensure we deliver a product that meets our quality and purity specifications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"170\" data-end=\"599\"\u003e\u003cstrong data-start=\"170\" data-end=\"185\"\u003eTiragolumab\u003c\/strong\u003e is a \u003cstrong data-start=\"191\" data-end=\"232\"\u003efully human IgG1κ monoclonal antibody\u003c\/strong\u003e that binds \u003cstrong data-start=\"244\" data-end=\"302\"\u003eTIGIT (T-cell immunoreceptor with Ig and ITIM domains)\u003c\/strong\u003e—an inhibitory immune checkpoint expressed on \u003cstrong data-start=\"348\" data-end=\"385\"\u003eCD8+ T cells, NK cells, and Tregs\u003c\/strong\u003e. Its core intent is to \u003cstrong data-start=\"409\" data-end=\"447\"\u003erelease TIGIT-mediated suppression\u003c\/strong\u003e and enhance anti-tumor immunity, most commonly in combination with \u003cstrong data-start=\"515\" data-end=\"558\"\u003ePD-L1 blockade (atezolizumab\/Tecentriq)\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"601\" data-end=\"884\"\u003e\u003cstrong data-start=\"601\" data-end=\"623\"\u003eRegulatory status:\u003c\/strong\u003e investigational (not FDA\/EMA-approved). Tiragolumab previously received \u003cstrong data-start=\"696\" data-end=\"736\"\u003eFDA Breakthrough Therapy Designation\u003c\/strong\u003e for PD-L1-high metastatic NSCLC \u003cstrong data-start=\"769\" data-end=\"805\"\u003ein combination with atezolizumab\u003c\/strong\u003e, based on early phase randomized data. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"886\" data-end=\"889\"\u003e\n\u003ch3 data-start=\"891\" data-end=\"953\"\u003e2) Target biology: why TIGIT matters (and why it’s tricky)\u003c\/h3\u003e\n\u003cp data-start=\"954\" data-end=\"1291\"\u003eTIGIT competes with the activating receptor \u003cstrong data-start=\"998\" data-end=\"1016\"\u003eCD226 (DNAM-1)\u003c\/strong\u003e for binding to \u003cstrong data-start=\"1032\" data-end=\"1047\"\u003eCD155 (PVR)\u003c\/strong\u003e and \u003cstrong data-start=\"1052\" data-end=\"1061\"\u003eCD112\u003c\/strong\u003e, and also delivers \u003cstrong data-start=\"1081\" data-end=\"1112\"\u003edirect inhibitory signaling\u003c\/strong\u003e via its cytoplasmic motifs. Net effect: \u003cstrong data-start=\"1153\" data-end=\"1197\"\u003ereduced T-cell and NK cytotoxic function\u003c\/strong\u003e, and often a more suppressive tumor microenvironment. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"1293\" data-end=\"1371\"\u003eThe therapeutic challenge is that TIGIT biology is \u003cstrong data-start=\"1344\" data-end=\"1370\"\u003ecell-context dependent\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-start=\"1372\" data-end=\"1595\"\u003e\n\u003cli data-start=\"1372\" data-end=\"1437\"\u003e\n\u003cp data-start=\"1374\" data-end=\"1437\"\u003eOn \u003cstrong data-start=\"1377\" data-end=\"1406\"\u003eeffector T cells\/NK cells\u003c\/strong\u003e, blockade can restore killing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1438\" data-end=\"1595\"\u003e\n\u003cp data-start=\"1440\" data-end=\"1595\"\u003eOn \u003cstrong data-start=\"1443\" data-end=\"1452\"\u003eTregs\u003c\/strong\u003e, TIGIT is often enriched; Fc-active antibodies may also alter Treg\/NK dynamics via effector functions. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1597\" data-end=\"1600\"\u003e\n\u003ch2 data-start=\"1602\" data-end=\"1637\"\u003e3) Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-start=\"1639\" data-end=\"1674\"\u003e3.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"1675\" data-end=\"1851\"\u003e\n\u003cli data-start=\"1675\" data-end=\"1851\"\u003e\n\u003cp data-start=\"1677\" data-end=\"1851\"\u003eTiragolumab \u003cstrong data-start=\"1689\" data-end=\"1740\"\u003eblocks TIGIT’s interaction with CD155 and CD112\u003c\/strong\u003e, reducing inhibitory signaling and promoting effector immune activity. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1853\" data-end=\"1893\"\u003e3.2 Systems-level “intended biology”\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"1894\" data-end=\"2543\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"1894\" data-end=\"1932\"\u003e\n\u003ctr data-start=\"1894\" data-end=\"1932\"\u003e\n\u003cth data-start=\"1894\" data-end=\"1901\" data-col-size=\"sm\"\u003eAxis\u003c\/th\u003e\n\u003cth data-start=\"1901\" data-end=\"1919\" data-col-size=\"md\"\u003eExpected effect\u003c\/th\u003e\n\u003cth data-start=\"1919\" data-end=\"1932\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"1947\" data-end=\"2543\"\u003e\n\u003ctr data-start=\"1947\" data-end=\"2097\"\u003e\n\u003ctd data-start=\"1947\" data-end=\"1962\" data-col-size=\"sm\"\u003eCD8+ T cells\u003c\/td\u003e\n\u003ctd data-start=\"1962\" data-end=\"2016\" data-col-size=\"md\"\u003e↑ effector function, less exhaustion-like signaling\u003c\/td\u003e\n\u003ctd data-start=\"2016\" data-end=\"2097\" data-col-size=\"md\"\u003eTIGIT blockade relieves inhibitory tone \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2098\" data-end=\"2219\"\u003e\n\u003ctd data-start=\"2098\" data-end=\"2109\" data-col-size=\"sm\"\u003eNK cells\u003c\/td\u003e\n\u003ctd data-start=\"2109\" data-end=\"2146\" data-col-size=\"md\"\u003e↑ cytotoxicity (context dependent)\u003c\/td\u003e\n\u003ctd data-start=\"2146\" data-end=\"2219\" data-col-size=\"md\"\u003eTIGIT is inhibitory on NK cells \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2220\" data-end=\"2395\"\u003e\n\u003ctd data-start=\"2220\" data-end=\"2228\" data-col-size=\"sm\"\u003eTregs\u003c\/td\u003e\n\u003ctd data-start=\"2228\" data-end=\"2287\" data-col-size=\"md\"\u003epotentially ↓ suppressive impact (depends on Fc biology)\u003c\/td\u003e\n\u003ctd data-start=\"2287\" data-end=\"2395\" data-col-size=\"md\"\u003eFc-active anti-TIGIT may deplete\/alter TIGIT+ Tregs in some models \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2396\" data-end=\"2543\"\u003e\n\u003ctd data-start=\"2396\" data-end=\"2423\" data-col-size=\"sm\"\u003eCombination with PD-(L)1\u003c\/td\u003e\n\u003ctd data-start=\"2423\" data-end=\"2443\" data-col-size=\"md\"\u003epotential synergy\u003c\/td\u003e\n\u003ctd data-start=\"2443\" data-end=\"2543\" data-col-size=\"md\"\u003edual-checkpoint release in the same tumor microenvironment \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2545\" data-end=\"2548\"\u003e\n\u003ch2 data-start=\"2550\" data-end=\"2599\"\u003e4) Pharmacokinetics and dosing (program-level)\u003c\/h2\u003e\n\u003cp data-start=\"2600\" data-end=\"2937\"\u003eAs an \u003cstrong data-start=\"2606\" data-end=\"2634\"\u003eIgG1 monoclonal antibody\u003c\/strong\u003e, tiragolumab follows typical mAb PK principles (FcRn recycling, slow clearance, distribution largely in vascular\/interstitial spaces). In pivotal programs it was dosed on a \u003cstrong data-start=\"2808\" data-end=\"2831\"\u003emulti-week schedule\u003c\/strong\u003e alongside atezolizumab ± chemotherapy (regimens varied by trial). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"2939\" data-end=\"2942\"\u003e\n\u003ch2 data-start=\"2944\" data-end=\"3001\"\u003e5) Clinical evidence (key trials and what they showed)\u003c\/h2\u003e\n\u003ch3 data-start=\"3003\" data-end=\"3068\"\u003e5.1 CITYSCAPE (Phase 2, first-line NSCLC): the early signal\u003c\/h3\u003e\n\u003cp data-start=\"3069\" data-end=\"3462\"\u003eIn \u003cstrong data-start=\"3072\" data-end=\"3085\"\u003eCITYSCAPE\u003c\/strong\u003e, \u003cstrong data-start=\"3087\" data-end=\"3117\"\u003etiragolumab + atezolizumab\u003c\/strong\u003e showed a \u003cstrong data-start=\"3127\" data-end=\"3164\"\u003eclinically meaningful improvement\u003c\/strong\u003e in \u003cstrong data-start=\"3168\" data-end=\"3225\"\u003eobjective response rate and progression-free survival\u003c\/strong\u003e versus placebo + atezolizumab as first-line treatment in metastatic NSCLC, with signals strongest in \u003cstrong data-start=\"3327\" data-end=\"3352\"\u003ePD-L1–high (TPS ≥50%)\u003c\/strong\u003e patients—this dataset underpinned Breakthrough Therapy Designation. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-start=\"3464\" data-end=\"3540\"\u003e5.2 SKYSCRAPER-01 (Phase 3, PD-L1–high NSCLC): did not confirm benefit\u003c\/h3\u003e\n\u003cp data-start=\"3541\" data-end=\"3870\"\u003eIn the Phase 3 confirmatory setting, \u003cstrong data-start=\"3578\" data-end=\"3608\"\u003eSKYSCRAPER-01 did not meet\u003c\/strong\u003e its \u003cstrong data-start=\"3613\" data-end=\"3634\"\u003eprimary endpoints\u003c\/strong\u003e of \u003cstrong data-start=\"3638\" data-end=\"3688\"\u003eoverall survival and investigator-assessed PFS\u003c\/strong\u003e for tiragolumab + atezolizumab vs atezolizumab alone in previously untreated PD-L1–high advanced NSCLC (final analyses presented publicly). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-start=\"3872\" data-end=\"3924\"\u003e5.3 SKYSCRAPER-02 (Phase 3, ES-SCLC): negative\u003c\/h3\u003e\n\u003cp data-start=\"3925\" data-end=\"4201\"\u003eIn untreated \u003cstrong data-start=\"3938\" data-end=\"3980\"\u003eextensive-stage small-cell lung cancer\u003c\/strong\u003e, adding tiragolumab to \u003cstrong data-start=\"4004\" data-end=\"4044\"\u003eatezolizumab + carboplatin\/etoposide\u003c\/strong\u003e \u003cstrong data-start=\"4045\" data-end=\"4083\"\u003edid not provide additional benefit\u003c\/strong\u003e over control for OS\/PFS; safety was generally consistent with expectations. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-start=\"4203\" data-end=\"4310\"\u003e5.4 SKYSCRAPER-06 (Phase II\/III, non-squamous NSCLC vs Keytruda regimen): halted for reduced efficacy\u003c\/h3\u003e\n\u003cp data-start=\"4311\" data-end=\"4553\"\u003eRoche reported \u003cstrong data-start=\"4326\" data-end=\"4343\"\u003eSKYSCRAPER-06\u003c\/strong\u003e (tiragolumab + atezolizumab + chemo vs pembrolizumab + chemo) \u003cstrong data-start=\"4406\" data-end=\"4427\"\u003emissed PFS and OS\u003c\/strong\u003e and showed \u003cstrong data-start=\"4439\" data-end=\"4473\"\u003ereduced efficacy vs comparator\u003c\/strong\u003e, leading Roche to \u003cstrong data-start=\"4492\" data-end=\"4510\"\u003ehalt the trial\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-start=\"4555\" data-end=\"4605\"\u003e5.5 Beyond lung cancer: exploratory programs\u003c\/h3\u003e\n\u003cp data-start=\"4606\" data-end=\"4871\"\u003eTiragolumab has been studied in other tumor types (e.g., PD-L1+ recurrent cervical cancer in a randomized phase II design), reflecting broad interest in TIGIT biology, but lung cancer was the most visible confirmatory path. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"4873\" data-end=\"4876\"\u003e\n\u003ch2 data-start=\"4878\" data-end=\"4932\"\u003e6) Safety and tolerability (most defensible points)\u003c\/h2\u003e\n\u003cp data-start=\"4933\" data-end=\"5065\"\u003eAcross large combination trials, the safety profile is broadly consistent with \u003cstrong data-start=\"5012\" data-end=\"5049\"\u003echeckpoint therapy + chemotherapy\u003c\/strong\u003epatterns, with:\u003c\/p\u003e\n\u003cul data-start=\"5066\" data-end=\"5419\"\u003e\n\u003cli data-start=\"5066\" data-end=\"5114\"\u003e\n\u003cp data-start=\"5068\" data-end=\"5114\"\u003e\u003cstrong data-start=\"5068\" data-end=\"5091\"\u003eimmune-mediated AEs\u003c\/strong\u003e (checkpoint class) and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5115\" data-end=\"5419\"\u003e\n\u003cp data-start=\"5117\" data-end=\"5419\"\u003e\u003cstrong data-start=\"5117\" data-end=\"5145\"\u003echemo-related toxicities\u003c\/strong\u003e when combined,\u003cbr\u003eplus trial-specific signals such as \u003cstrong data-start=\"5197\" data-end=\"5225\"\u003einjection-site reactions\u003c\/strong\u003e reported in some combinations (where applicable). For SKYSCRAPER-06, Roche reported safety consistent with prior studies despite stopping for efficacy. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"5421\" data-end=\"5544\"\u003e\u003cem data-start=\"5421\" data-end=\"5544\"\u003e(For any program write-up, it’s best to ground AE language in the actual paper\/CSR for the exact regimen and population.)\u003c\/em\u003e\u003c\/p\u003e\n\u003chr data-start=\"5546\" data-end=\"5549\"\u003e\n\u003ch2 data-start=\"5551\" data-end=\"5619\"\u003e7) Why the Phase 2 signal didn’t translate (scientific synthesis)\u003c\/h2\u003e\n\u003cp data-start=\"5620\" data-end=\"5708\"\u003eThe best-supported, non-speculative interpretation from the field and recent reviews is:\u003c\/p\u003e\n\u003col data-start=\"5710\" data-end=\"6452\"\u003e\n\u003cli data-start=\"5710\" data-end=\"5975\"\u003e\n\u003cp data-start=\"5713\" data-end=\"5975\"\u003e\u003cstrong data-start=\"5713\" data-end=\"5765\"\u003eTIGIT biology is redundant and context-specific.\u003c\/strong\u003e\u003cbr data-start=\"5765\" data-end=\"5768\"\u003eMultiple inhibitory axes (PD-1\/PD-L1, LAG-3, TIM-3, etc.) and variable ligand landscapes can dilute the incremental benefit of TIGIT blockade in Phase 3 populations. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5977\" data-end=\"6250\"\u003e\n\u003cp data-start=\"5980\" data-end=\"6250\"\u003e\u003cstrong data-start=\"5980\" data-end=\"6042\"\u003eFc biology and cell-type expression complicate net effect.\u003c\/strong\u003e\u003cbr data-start=\"6042\" data-end=\"6045\"\u003eTIGIT is expressed on both effector and regulatory compartments; Fc-active antibodies can have competing effects depending on tumor context and immune composition. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6252\" data-end=\"6452\"\u003e\n\u003cp data-start=\"6255\" data-end=\"6452\"\u003e\u003cstrong data-start=\"6255\" data-end=\"6308\"\u003ePhase 2 enrichment effects may not hold at scale.\u003c\/strong\u003e\u003cbr data-start=\"6308\" data-end=\"6311\"\u003eCITYSCAPE’s encouraging PD-L1-high subgroup signals did not reproduce in confirmatory NSCLC trials. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-start=\"6454\" data-end=\"6457\"\u003e\n\u003ch2 data-start=\"6459\" data-end=\"6476\"\u003e8) Bottom line\u003c\/h2\u003e\n\u003cp data-start=\"6477\" data-end=\"6922\"\u003e\u003cstrong data-start=\"6477\" data-end=\"6492\"\u003eTiragolumab\u003c\/strong\u003e is a leading \u003cstrong data-start=\"6506\" data-end=\"6520\"\u003eanti-TIGIT\u003c\/strong\u003e antibody that showed promising Phase 2 activity with atezolizumab in NSCLC (CITYSCAPE) and earned \u003cstrong data-start=\"6619\" data-end=\"6659\"\u003eFDA Breakthrough Therapy Designation\u003c\/strong\u003e, but multiple later-stage studies in lung cancer—including \u003cstrong data-start=\"6719\" data-end=\"6750\"\u003eSKYSCRAPER-01, -02, and -06\u003c\/strong\u003e—failed to demonstrate confirmatory benefit, with SKYSCRAPER-06 halted for reduced efficacy versus a pembrolizumab-based standard.\u003c\/p\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684837552466,"sku":null,"price":4500.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/tiragolumab_10mg.png?v=1770834781","url":"https:\/\/sciencepeptideslab.com\/products\/tiragolumabrg6058-mtig7192a-10mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}